Integral Diagnostics Ltd
ASX:IDX
Integral Diagnostics Ltd
ASX:IDX
Price:
2.44 AUD
-2.4%
Market Closed
Updated:
May 10, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
21.1
Current
22.3
Median
12.6
Industry
Lower
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=21.1
Enterprise Value
/
895.2m
EBITDA
42.4m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| AU |
|
Integral Diagnostics Ltd
ASX:IDX
|
569.6m AUD | 21.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
99.7B USD | 9.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
91.3B EUR | 9.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
69.7B USD | 8.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
17.4B USD | 12.1 | |
| DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.8B EUR | 10.1 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
15.3B USD | 10.9 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.4B EUR | 6.8 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
11.3B EUR | 6.8 | |
| US |
|
DaVita Inc
NYSE:DVA
|
12.1B USD | 8.3 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -23.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
9.7
2-Years Forward
EV/EBITDA
8.6
3-Years Forward
EV/EBITDA
7.8
You don't have any saved screeners yet
